- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07617727
A Phase I Study of JSKN021 in Advanced Solid Tumors
24 août 2026 mis à jour par: Jiangsu Alphamab Biopharmaceuticals Co., Ltd
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of JSKN021 in Advanced Malignant Solid Tumors
This is a Phase I, open-label, multi-center, first-in-human (FIH) clinical trial designed to evaluate the safety, tolerability, pharmacokinetic (PK) profiles, and the preliminary antitumor activity of JSKN021 in advanced malignant solid tumors.
Aperçu de l'étude
Statut
Recrutement
Les conditions
Intervention / Traitement
Type d'étude
Interventionnel
Inscription (Estimé)
199
Phase
- La phase 1
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Coordonnées de l'étude
- Nom: Jian Zhang, MD
- Numéro de téléphone: 08602134778299
- E-mail: syner2000@163.com
Lieux d'étude
-
-
Fujian
-
Fuzhou, Fujian, Chine, 350014
- Recrutement
- Fujian Cancer Hospital
-
-
Guangxi
-
Nanning, Guangxi, Chine
- Recrutement
- Tumor Hospital of Guangxi Medical University
-
-
Heilongjiang
-
Harbin, Heilongjiang, Chine, 150081
- Recrutement
- Harbin Medical University Cancer Hospital
-
-
Hubei
-
Wuhan, Hubei, Chine
- Recrutement
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
-
Wuhan, Hubei, Chine, 430079
- Recrutement
- Hubei Cancer Hospital
-
-
Jiangsu
-
Nanjing, Jiangsu, Chine
- Recrutement
- Jiangsu Province Hospital
-
Xuzhou, Jiangsu, Chine
- Recrutement
- Xuzhou Central Hospital
-
-
Shandong
-
Jining, Shandong, Chine
- Recrutement
- Affiliated Hospital of Jining Medical College
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Chine
- Recrutement
- Fudan University Shanghai Cancer Center
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, Chine, 300060
- Recrutement
- Tianjin Medical University Cancer Institute & Hospital
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Non
La description
Inclusion Criteria:
- Voluntarily participate and sign the informed consent form.
- Age ≥ 18 years old, male or female.
- Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1.
- Expected survival ≥ 3 months.
- Histologically or cytologically confirmed malignant solid tumors confirmed by histology and/or cytology, who have failed previous standard treatment (disease progression), are intolerant to standard treatment, or have no access to standard treatment.
- At least one measurable lesion at baseline according to RECIST 1.1 criteria.
- Adequate organ function.
- Female subjects of childbearing potential or male subjects whose partners are of childbearing potential agree to use effective contraceptive measures.
- Female subjects of childbearing potential must have a negative serum/urine pregnancy test within 7 days before the first dose.
- Be able and willing to comply with the visits, treatment plans, laboratory tests, and other study-related procedures specified in the study protocol.
- Adequate washout period of previous therapy before the first dose.
Exclusion Criteria:
- Complicated with other malignant tumors within 3 years before the first dose.
- History of brainstem, meningeal metastasis, spinal cord metastasis or compression, or carcinomatous meningitis; presence of active brain metastasis.
- Screening imaging shows tumor invasion, compression, or occurrence in surrounding important organs or risk of esophagotracheal fistula or esophagopleural fistula.
- Presence of clinically severe respiratory impairment caused by pulmonary disease complications.
- Presence of the risk factors related to interstitial lung disease (ILD) or non-infectious pneumonia:
- Presence of cardiovascular and cerebrovascular diseases or cardiovascular and cerebrovascular risk factors.
- Uncontrolled infection.
- Received live vaccines within 28 days before the first dose, or plan to receive live vaccines during the study period.
- Toxicity of previous anti-tumor treatment has not fully or partially recovered.
- Known allergy to any component of the study drug, or history of severe allergic reactions to other antibody drugs.
- Pregnant and/or lactating women, or planning to become pregnant during the study period.
- Known history of mental illness, substance abuse, alcoholism, etc., or other situations that the investigator deems may affect the safety or compliance of the study drug treatment.
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation séquentielle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Cohorte 2 d'escalade de dose
|
JSKN021 administered intravenously at selected dose levels according to protocol
|
|
Expérimental: Cohorte 3 d'escalade de dose
|
JSKN021 administered intravenously at selected dose levels according to protocol
|
|
Expérimental: Cohorte d'escalade de dose 4
|
JSKN021 administered intravenously at selected dose levels according to protocol
|
|
Expérimental: Cohorte d'escalade de dose 5
|
JSKN021 administered intravenously at selected dose levels according to protocol
|
|
Expérimental: Cohorte d'escalade de dose 6
|
JSKN021 administered intravenously at selected dose levels according to protocol
|
|
Expérimental: Dose escalation cohort 1
|
JSKN021 administered intravenously at selected dose levels according to protocol
|
|
Expérimental: Dose optimization cohort 1
|
JSKN021 administered intravenously at selected dose levels according to protocol
|
|
Expérimental: Dose optimization cohort 2
|
JSKN021 administered intravenously at selected dose levels according to protocol
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Frequency and severity of treatment-emergent adverse events (TEAEs), treatment-related adverse events (TRAEs), serious adverse events (SAEs), etc (Safety and tolerability of JSKN021)
Délai: From the first dose to 30 days after the last dose or until initiation of new anti-tumor treatment, whichever comes first.
|
Frequency and severity of treatment-emergent adverse events (TEAEs), treatment-related adverse events (TRAEs), serious adverse events (SAEs), etc.; abnormalities in physical examinations, laboratory tests, electrocardiograms, and other safety measures.
|
From the first dose to 30 days after the last dose or until initiation of new anti-tumor treatment, whichever comes first.
|
|
Dose-limiting toxicity (DLT)
Délai: 21 days from the first dose
|
Incidence of dose-limiting toxicity (DLT) in each dose group.
|
21 days from the first dose
|
|
Optimal biological dose (OBD) and/or recommended Phase Ⅱ dose (RP2D) of JSKN021.
Délai: Up to 24 months
|
Based on safety and efficacy data.
|
Up to 24 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Objective response rate (ORR)
Délai: Up to 24months
|
Objective response rate (ORR) was defined as the proportion of participants who achieve either complete response [CR] or partial response [PR] per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
|
Up to 24months
|
|
Duration of response (DoR)
Délai: Up to 24months
|
Duration of response (DoR) assessed according to RECIST v1.1.
|
Up to 24months
|
|
Disease control rate (DCR)
Délai: Up to 24months
|
Disease control rate (DCR) assessed according to RECIST v1.1.
|
Up to 24months
|
|
Progression-Free Survival (PFS)
Délai: Up to 24months
|
Progression-free survival (PFS) is defined as the time from the date of initial administration till the first documentation of disease progression or death due to any cause (whichever occurs first).
|
Up to 24months
|
|
Overall survival(OS)
Délai: Up to 24months
|
Overall Survival (OS) is defined as the time from the date of initial administration till death due to any cause.
|
Up to 24months
|
|
Immunogenicity
Délai: Up to 24months
|
Incidence and titer changes of anti-drug antibodies (ADAs) and neutralizing antibodies (Nabs, if applicable)
|
Up to 24months
|
|
Maximum concentration (Cmax) of JSKN021
Délai: Up to 24months
|
Maximum concentration (Cmax) of JSKN021
|
Up to 24months
|
|
Time to maximum concentration (Tmax) of JSKN021
Délai: Up to 24 months.
|
Time to maximum concentration (Tmax) of JSKN021
|
Up to 24 months.
|
|
Trough concentration (Ctrough) of JSKN021
Délai: Up to 24 months
|
Trough concentration (Ctrough) of JSKN021
|
Up to 24 months
|
|
Area under the concentration-time curve of JSKN021
Délai: Up to 24 months
|
Area under the concentration-time curve of JSKN021
|
Up to 24 months
|
|
Volume of distribution (V) of JSKN021
Délai: Up to 24 months
|
Volume of distribution (V) of JSKN021
|
Up to 24 months
|
|
Elimination half-life (t1/2) of JSKN021
Délai: Up to 24 months
|
Elimination half-life (t1/2) of JSKN021
|
Up to 24 months
|
|
Clearance (CL) of JSKN021
Délai: Up to 24 months
|
Clearance (CL) of JSKN021
|
Up to 24 months
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Réel)
2 juin 2026
Achèvement primaire (Estimé)
31 octobre 2028
Achèvement de l'étude (Estimé)
31 mai 2029
Dates d'inscription aux études
Première soumission
20 mai 2026
Première soumission répondant aux critères de contrôle qualité
29 mai 2026
Première publication (Réel)
1 juin 2026
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
26 août 2026
Dernière mise à jour soumise répondant aux critères de contrôle qualité
24 août 2026
Dernière vérification
1 août 2026
Plus d'information
Termes liés à cette étude
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
NON
Description du régime IPD
No individual participant data will be shared.
The informed consent form does not include provisions for sharing de-identified participant-level data with researchers outside the study team.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Non
Étudie un produit d'appareil réglementé par la FDA américaine
Non
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .